Goldman Sachs invested in AstraZeneca-founded Viela Bio's latest round, taking the 6 Dimensions Capital-backed biopharmaceutical developer's total funding to more than $300m.
Viela Bio, a US-based inflammation and autoimmune disease drug developer backed by corporate-founded investment firm 6 Dimensions Capital, completed a $75m series B round on Monday.
The round was led by investment firm HBM Healthcare Investments and included investment bank Goldman Sachs, Temasek, Viking Global Investors, Terra Magnum Capital Partners, Barer and Son Capital, Cormorant Asset Management and unnamed existing investors.
Founded in 2018 by pharmaceutical firm AstraZeneca, Viela Bio is advancing drug candidates to treat severe autoimmune and inflammatory…
